



University of HUDDERSFIELD

University of Huddersfield Repository

Alcorn, J., Biyani, S., Weston, S., Sundaram, R., Burton, Rob, Topping, Annie and Stephenson, John

Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG)

Original Citation

Alcorn, J., Biyani, S., Weston, S., Sundaram, R., Burton, Rob, Topping, Annie and Stephenson, John (2015) Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG). In: EAU 15: European Association of Urology, 20th-24th March 2015, Madrid, Spain.

This version is available at <http://eprints.hud.ac.uk/id/eprint/23464/>

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:


- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

<http://eprints.hud.ac.uk/>

Retrospective analysis of patients' experience to intravesical Bacillus Calmette-Guerin (BCG)

J. Alcorn, S. Biyani, P. Weston, S.
Sundaram, R. Burton, A. Topping,
J. Stephenson



Why & what did we do?

Why?

- Gold standard
- Bladder cancer incidence rates are highest in developed countries, especially Northern America and Europe
- BCG treatment induction & maintenance has significant benefits, but also has significant side effects that tend to be seen within the first 12 months of treatment
- To analyse the reasons for treatment interruption in everyday clinical practice in a large district hospital

How did we do it?

- Appropriate ethical approval
- Quantitative data
 - 01/01/04 – 31/12/11
 - Retrospective case note review of 234 cases
 - Diagnosis of NMIBC, grade 3 Ta/1 or CIS, aged 18 years or over
 - Conaught Strain
 - Administered as per SWOG
 - Collected using a specially designed data extraction tool
 - Convenience sample
 - Analysed through IBM SPSS v20

The treatment journey of patients receiving BCG treatment for superficial bladder cancer – Audit tool

Demographics: Id No: <input type="text"/> Sex: <input type="checkbox"/> M <input type="checkbox"/> F Age: <input type="text"/> Hospital site: <input type="checkbox"/> PGI <input type="checkbox"/> PGI DDH		Co-morbidities: 1. <input type="text"/> 2. <input type="text"/> 3. <input type="text"/> 4. <input type="text"/> 5. <input type="text"/> 6. <input type="text"/>		<table border="1"> <thead> <tr> <th>CYCLE</th> <th>DATE</th> <th>SIDE EFFECTS</th> </tr> </thead> <tbody> <tr> <td rowspan="6">Cycle 1 – Induction</td> <td>0 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="5">6 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">Cycle 2 – Maintenance</td> <td>3 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td>3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">Cycle 3 – Maintenance</td> <td>6 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td>3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="3">Cycle 4 – Maintenance</td> <td>12 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="3">Cycle 5 – Maintenance</td> <td>18 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="3">Cycle 6 – Maintenance</td> <td>24 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="3">Cycle 7 – Maintenance</td> <td>30 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="3">Cycle 8 – Maintenance</td> <td>36 months</td> <td>/ /20</td> <td></td> </tr> <tr> <td rowspan="2">3 weeks</td> <td>/ /20</td> <td></td> </tr> <tr> <td>/ /20</td> <td></td> </tr> </tbody> </table>			CYCLE	DATE	SIDE EFFECTS	Cycle 1 – Induction	0 months	/ /20		6 weeks	/ /20		/ /20		/ /20		/ /20		/ /20		Cycle 2 – Maintenance	3 months	/ /20		3 weeks	/ /20		Cycle 3 – Maintenance	6 months	/ /20		3 weeks	/ /20		Cycle 4 – Maintenance	12 months	/ /20		3 weeks	/ /20		/ /20		Cycle 5 – Maintenance	18 months	/ /20		3 weeks	/ /20		/ /20		Cycle 6 – Maintenance	24 months	/ /20		3 weeks	/ /20		/ /20		Cycle 7 – Maintenance	30 months	/ /20		3 weeks	/ /20		/ /20		Cycle 8 – Maintenance	36 months	/ /20		3 weeks	/ /20		/ /20	
CYCLE	DATE	SIDE EFFECTS																																																																																	
Cycle 1 – Induction	0 months	/ /20																																																																																	
	6 weeks	/ /20																																																																																	
		/ /20																																																																																	
		/ /20																																																																																	
		/ /20																																																																																	
		/ /20																																																																																	
Cycle 2 – Maintenance	3 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
Cycle 3 – Maintenance	6 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
Cycle 4 – Maintenance	12 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
		/ /20																																																																																	
Cycle 5 – Maintenance	18 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
		/ /20																																																																																	
Cycle 6 – Maintenance	24 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
		/ /20																																																																																	
Cycle 7 – Maintenance	30 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
		/ /20																																																																																	
Cycle 8 – Maintenance	36 months	/ /20																																																																																	
	3 weeks	/ /20																																																																																	
		/ /20																																																																																	
Cancer Staging: Grade 3: <input type="checkbox"/> pTa: <input type="checkbox"/> pT1: <input type="checkbox"/> CIS: <input type="checkbox"/>		Information given: Contact numbers: <input type="checkbox"/> Y <input type="checkbox"/> N Leaflets: <input type="checkbox"/> Y <input type="checkbox"/> N Treatment discussion: <input type="checkbox"/> Y <input type="checkbox"/> N Other: <input type="text"/>																																																																																	
Treatment: Date commenced: <input type="text"/> Date stopped: <input type="text"/> Course completed: <input type="checkbox"/> Y <input type="checkbox"/> N Reason for stopping: <input type="text"/> If no: <input type="checkbox"/> Total no. instillations: <input type="text"/> Total no. of cycles: <input type="text"/> No. of complete cycles: <input type="text"/>		Symptoms during treatment: 1. <input type="text"/> 2. <input type="text"/> 3. <input type="text"/> 4. <input type="text"/> 5. <input type="text"/> 6. <input type="text"/> 7. <input type="text"/> 8. <input type="text"/> 9. <input type="text"/>																																																																																	
COMMENTS: <input type="text"/> <input type="text"/> <input type="text"/>																																																																																			

What did we find?

- Issues
 - Data extraction tool
 - Paper to electronic
 - Recorded information
- Results
 - 61% \geq 70yrs. From these:
 - 92% completed induction, 80% started maintenance
 - 56% completed 1 year and 5% completed 3 years
 - 43% received counselling
 - 10% nurse specialist contact details
 - 65% had at least 1 symptom (45% within 35 days)
 - 40% experienced pain

Conclusion & next steps

- Conclusion
 - Severe toxicity resulted in discontinuation of therapy in the majority
 - The majority withdraw in the first year
 - Surprising that those who had contact with a nurse specialist or received written information were more likely to withdraw
 - Targeted support
- Next steps
 - Interview patients who have withdrawn for their experience
 - Look at the consultation e.g. grade of Dr
 - Review our practice